Nordic CRO Larix signs Master Service Agreement with Viedoc
PRESS RELEASE / 2019-06-25
Nordic full-service CRO Larix has signed a master service agreement with Viedoc and will soon initiate the first clinical study powered by the Viedoc EDC system.
“Viedoc’s big selling points are their streamlined setup process and a highly user-friendly interface. That’s exactly what our small- and middle-sized clients in the biotech industry are looking for in an EDC system,” says Lisa Thell, Director Data Management at Larix.
Larix works with several different EDC systems depending on the client and study at hand.
“With Viedoc, we get an EDC system which allows our clients to focus entirely on their research, instead of spending large amounts of time on lengthy setup processes and learning how to manage the system. We want the best solution for every given study when offering an EDC solution to our clients.”
“We’re excited to start working with Larix and get the first study underway. Our goal from the start has been to make electronic data capture smarter, faster and easier than ever before – so it’s rewarding that Larix has chosen our system based on those exact factors,” says Henrik Blombergsson, COO and co-founder Viedoc.
Larix is a family founded, privately-owned CRO offering solutions in statistics, data management, clinical operations, medical writing, pharmacovigilance and data monitoring committees. Larix was founded in 2001 by Klaus Juel Olsen. In 2003, the company expanded with services within data management, and additional statisticians were employed. The clinical research service was added in 2008, simultaneously with an independent QA function. In 2010 the services were broadened to include pharmacovigilance. In 2015 Larix expanded to Sweden, Norway and Finland and as next step the Swedish office is now moving into Medicon Village in Lund. With more than 60 highly-qualified employees Larix has broad experience and therapeutic expertise in all aspects of clinical development in the biotechnology, medical device and pharmaceutical industries.
For more information, please contact: